Share Price and Basic Stock Data
Last Updated: January 2, 2026, 5:33 pm
| PEG Ratio | 0.29 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Entero Healthcare Solutions Ltd operates within the pharmaceuticals sector, reporting a share price of ₹1,116 and a market capitalization of ₹4,856 Cr. The company has demonstrated a robust upward trajectory in sales, which stood at ₹3,300 Cr for the fiscal year ending March 2023, a significant increase from ₹2,522 Cr in March 2022. As per trailing twelve months (TTM) data, sales rose to ₹5,673 Cr, indicating a continued growth trend. Quarterly sales figures also reflect this momentum, with the company achieving ₹996 Cr in sales for September 2023, and further rising to ₹1,301 Cr by September 2024. Such growth in revenue highlights Entero’s effective market strategies and operational efficiencies, particularly as the operating profit margin (OPM) increased from a low of 2% in March 2020 to 4% in March 2025. This upward trend in revenue generation positions Entero favorably within the competitive landscape of the pharmaceutical industry.
Profitability and Efficiency Metrics
Entero Healthcare has made notable strides in profitability, with the net profit reported at ₹107 Cr for the fiscal year ending March 2025, a considerable recovery from previous years marked by losses. The company recorded an operating profit of ₹172 Cr for the same period, reflecting a marked improvement in operational efficiency. The operating profit margin (OPM) has steadily improved from 2% in March 2020 to 3% in March 2024, and further to 4% by March 2025. Entero’s return on equity (ROE) stood at 5.49% for the year ending March 2025, showcasing the effectiveness of its capital utilization. However, the company reported a cash conversion cycle (CCC) of 80 days, slightly higher than the industry average, indicating potential room for improvement in working capital management. Additionally, the interest coverage ratio (ICR) of 5.07x signifies healthy earnings relative to interest obligations, enhancing overall financial stability.
Balance Sheet Strength and Financial Ratios
Entero’s balance sheet reflects a solid financial foundation with total assets reported at ₹2,703 Cr as of March 2025. The company has reserves amounting to ₹1,681 Cr, a significant recovery from negative reserves in previous years, which indicates improved retained earnings and financial health. Total borrowings stood at ₹443 Cr, translating to a debt-to-equity ratio of 0.17, which is relatively low and suggests a conservative approach to leveraging. The price-to-book value (P/BV) ratio of 2.87x implies that the stock is priced at a premium compared to its book value, potentially reflecting investor confidence in future growth. The current ratio of 2.46 indicates strong liquidity, allowing the company to meet short-term obligations comfortably. These financial ratios collectively portray Entero as a financially stable entity with manageable debt levels and sufficient liquidity to support its operations and growth initiatives.
Shareholding Pattern and Investor Confidence
Entero’s shareholding pattern reveals a diverse ownership structure, with promoters holding 52.42% of the company as of March 2025. Foreign institutional investors (FIIs) have reduced their stake to 14.68%, down from a higher percentage in earlier quarters, suggesting cautious sentiment among foreign investors. Domestic institutional investors (DIIs) hold 9.64%, while public shareholders account for 23.26% of the equity. The total number of shareholders has seen fluctuations, with 36,334 recorded as of September 2025. This diversity in ownership can be viewed positively, as it indicates a broad base of support. However, the declining FII interest may raise concerns regarding long-term investor confidence. Overall, the stable promoter holding coupled with a significant public stake reflects a balanced approach to governance and accountability within the company.
Outlook, Risks, and Final Insight
Looking ahead, Entero Healthcare Solutions Ltd is poised for further growth, driven by increasing sales and improving profitability metrics. However, the company faces several risks, including potential fluctuations in raw material prices and regulatory challenges inherent in the pharmaceutical sector. The high cash conversion cycle may also pose a risk to liquidity if not managed effectively. Nevertheless, strengths such as a solid balance sheet, improving profit margins, and a diverse shareholder base provide a cushion against these risks. Should Entero continue to enhance its operational efficiencies and maintain growth in sales, it could solidify its position in the market. Conversely, adverse market conditions or regulatory setbacks could impede progress. The company’s ability to navigate these challenges will be crucial in determining its future trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 217/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,749 Cr. | 435 | 479/192 | 98.3 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,252.27 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 |
| Expenses | 810 | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 | 1,509 |
| Operating Profit | 19 | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 | 62 |
| OPM % | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% | 4% |
| Other Income | 2 | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 | 5 |
| Interest | 13 | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 | 12 |
| Depreciation | 5 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 10 |
| Profit before tax | 2 | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 | 45 |
| Tax % | -44% | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% | 18% |
| Net Profit | 4 | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 | 37 |
| EPS in Rs | 8.05 | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 | 7.26 |
Last Updated: December 27, 2025, 2:37 am
Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 1,571.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,404.00 Cr. (Jun 2025) to 1,571.00 Cr., marking an increase of 167.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,354.00 Cr. (Jun 2025) to 1,509.00 Cr., marking an increase of 155.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 50.00 Cr. (Jun 2025) to 62.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Sep 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 4.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Jun 2025) to 5.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 12.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11.00 Cr. (Jun 2025) to 12.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Jun 2025) to 45.00 Cr., marking an increase of 9.00 Cr..
- For Tax %, as of Sep 2025, the value is 18.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Jun 2025) to 18.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Jun 2025) to 37.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 7.26. The value appears strong and on an upward trend. It has increased from 6.39 (Jun 2025) to 7.26, marking an increase of 0.87.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:47 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,673 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,462 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 211 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 25 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 44 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 35 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 158 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 128 |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 25.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -1600.00% | -93.33% | 62.07% | 463.64% | 167.50% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1506.67% | 155.40% | 401.57% | -296.14% |
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 73% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: December 10, 2025, 4:15 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 | 1,723 |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 | 443 |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 | 642 |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 | 627 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 | 67 |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 | 2,158 |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 | 2,851 |
Below is a detailed analysis of the balance sheet data for Entero Healthcare Solutions Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 44.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 44.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,723.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,681.00 Cr. (Mar 2025) to 1,723.00 Cr., marking an increase of 42.00 Cr..
- For Borrowings, as of Sep 2025, the value is 443.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 385.00 Cr. (Mar 2025) to 443.00 Cr., marking an increase of 58.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 642.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 593.00 Cr. (Mar 2025) to 642.00 Cr., marking an increase of 49.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,851.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 627.00 Cr.. The value appears strong and on an upward trend. It has increased from 559.00 Cr. (Mar 2025) to 627.00 Cr., marking an increase of 68.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 67.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 9.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,158.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,085.00 Cr. (Mar 2025) to 2,158.00 Cr., marking an increase of 73.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,851.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,703.00 Cr. (Mar 2025) to 2,851.00 Cr., marking an increase of 148.00 Cr..
Notably, the Reserves (1,723.00 Cr.) exceed the Borrowings (443.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -580.00 | -705.00 | -950.00 | 63.00 | -226.00 | -213.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 |
| ROCE % | 1% | 1% | 5% | 7% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Invesco India Contra Fund | 1,577,379 | 0.81 | 167.63 | N/A | N/A | N/A |
| Invesco India ELSS Tax Saver Fund | 450,000 | 1.69 | 47.82 | N/A | N/A | N/A |
| Invesco India Aggressive Hybrid Fund | 30,000 | 0.38 | 3.19 | N/A | N/A | N/A |
| HSBC Tax Saver Equity Fund | 21,400 | 0.92 | 2.27 | N/A | N/A | N/A |
| Invesco India Equity Savings Fund | 17,000 | 0.43 | 1.81 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 21.80 | 10.81 | -3.10 | -9.22 | -5.29 |
| Diluted EPS (Rs.) | 21.76 | 10.81 | -3.10 | -9.22 | -5.29 |
| Cash EPS (Rs.) | 31.75 | 14.90 | 31.94 | -25.16 | 92.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Revenue From Operations / Share (Rs.) | 1171.23 | 901.80 | 8025.80 | 6550.82 | 177973.70 |
| PBDIT / Share (Rs.) | 48.51 | 29.03 | 169.07 | 75.12 | 2547.60 |
| PBIT / Share (Rs.) | 41.45 | 23.28 | 110.13 | 23.81 | 920.00 |
| PBT / Share (Rs.) | 31.89 | 8.17 | -8.97 | -51.46 | -1083.80 |
| Net Profit / Share (Rs.) | 24.69 | 9.15 | -27.00 | -76.46 | -1535.40 |
| NP After MI And SOA / Share (Rs.) | 21.79 | 8.99 | -28.11 | -77.71 | -1553.70 |
| PBDIT Margin (%) | 4.14 | 3.21 | 2.10 | 1.14 | 1.43 |
| PBIT Margin (%) | 3.53 | 2.58 | 1.37 | 0.36 | 0.51 |
| PBT Margin (%) | 2.72 | 0.90 | -0.11 | -0.78 | -0.60 |
| Net Profit Margin (%) | 2.10 | 1.01 | -0.33 | -1.16 | -0.86 |
| NP After MI And SOA Margin (%) | 1.86 | 0.99 | -0.35 | -1.18 | -0.87 |
| Return on Networth / Equity (%) | 5.49 | 2.38 | 0.00 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 9.70 | 5.80 | 6.61 | 1.38 | 1.68 |
| Return On Assets (%) | 3.50 | 1.66 | -0.88 | -2.65 | -1.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | -0.45 | -0.64 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.16 | -5.45 | -4.92 | -4.46 |
| Asset Turnover Ratio (%) | 2.02 | 2.15 | 2.71 | 2.57 | 0.00 |
| Current Ratio (X) | 2.46 | 3.34 | 1.64 | 1.84 | 2.19 |
| Quick Ratio (X) | 1.68 | 2.64 | 1.09 | 1.17 | 1.35 |
| Inventory Turnover Ratio (X) | 9.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.07 | 1.92 | 1.42 | 0.99 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 3.58 | 1.61 | 0.77 | -0.01 | 0.23 |
| Enterprise Value (Cr.) | 5029.50 | 3669.42 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.98 | 0.93 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 23.83 | 29.06 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 2.62 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
- For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
- For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
- For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
- For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
- For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.43. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 9.43, marking an increase of 9.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
- Net Profit Margin: 2.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 44 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sujesh Vasudevan | Chairperson (NonExe.&Ind.Director) |
| Mr. Prabhat Agrawal | Managing Director & CEO |
| Mr. Prem Sethi | Whole Time Director & COO |
| Mr. Rajesh Shashikant Dalal | Ind. Non-Executive Director |
| Ms. Sandhya Gadkari Sharma | Ind. Non-Executive Director |
| Mr. Arun Sadhanandham | Non Exe.Non Ind.Director |
| Ms. Sumona Chakraborty | Non Exe.Non Ind.Director |
| Mr. Kevin Rohitbhai Daftary | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd's intrinsic value (as of 03 January 2026) is ₹820.69 which is 26.98% lower the current market price of ₹1,124.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹4,866 Cr. market cap, FY2025-2026 high/low of ₹1,565/944, reserves of ₹1,723 Cr, and liabilities of ₹2,851 Cr.
What is the Market Cap of Entero Healthcare Solutions Ltd?
The Market Cap of Entero Healthcare Solutions Ltd is 4,866 Cr..
What is the current Stock Price of Entero Healthcare Solutions Ltd as on 03 January 2026?
The current stock price of Entero Healthcare Solutions Ltd as on 03 January 2026 is ₹1,124.
What is the High / Low of Entero Healthcare Solutions Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Entero Healthcare Solutions Ltd stocks is ₹1,565/944.
What is the Stock P/E of Entero Healthcare Solutions Ltd?
The Stock P/E of Entero Healthcare Solutions Ltd is 44.0.
What is the Book Value of Entero Healthcare Solutions Ltd?
The Book Value of Entero Healthcare Solutions Ltd is 406.
What is the Dividend Yield of Entero Healthcare Solutions Ltd?
The Dividend Yield of Entero Healthcare Solutions Ltd is 0.00 %.
What is the ROCE of Entero Healthcare Solutions Ltd?
The ROCE of Entero Healthcare Solutions Ltd is 8.71 %.
What is the ROE of Entero Healthcare Solutions Ltd?
The ROE of Entero Healthcare Solutions Ltd is 5.63 %.
What is the Face Value of Entero Healthcare Solutions Ltd?
The Face Value of Entero Healthcare Solutions Ltd is 10.0.